

Supplemental Document:

Figure S1:




Figure S1: Decreased levels of miRs are detected in the plasma of PTLD+ pediatric transplant recipients with monomorphic or polymorphic lesions as compared to controls. Concentrations of miR-17, miR-19, miR-106a, miR-155 and miR-194 were measured by qPCR in plasma of PTLD+ patients with early lesions, monomorphic/polymorphic lesions and matched controls. miR-106a, controls vs monomorphic/polymorphic lesions, $p = 0.047$ by one-way ANOVA.

Figure S2:






Figure S2: The expression of miRs 17, 19, 106a, 155 and 194 did not differ significantly between the recipients of heart, kidney, liver and visceral transplants within PTLD+ and control groups. Concentrations of miR-17, miR-19, miR-106a, miR-155 and miR-194 were measured by qPCR in plasma of recipients of heart, kidney, liver and visceral transplant.

Figure S3:


A.




Case 5




Case 6



Case 7




Case 8




B.


Control 1




Control 2



Control 3



Control 4






Figure S3: Longitudinal analysis of plasma miRNA expression. (A) Concentrations of miR-17, miR-19, miR-106a, miR-155 and miR-194 were measured by qPCR in plasma samples collected at multiple timepoints post-transplant from PTLD+ patients (n = 8). **(B)** Concentrations of miR-17, miR-19, miR-106a, miR-155 and miR-194 were measured by qPCR in plasma samples collected post-transplant from control patients at timepoints matched with paired PTLD+ patients (n = 8).

Figure S4:




Figure S4: Decreased levels of miRs are detected in the EV of PTLD+ pediatric transplant recipients with monomorphic or polymorphic lesions as compared to controls. Concentrations of miR-17, miR-19, miR-106a, miR-155 and miR-194 were measured by qPCR in plasma of PTLD+ patients with early lesions, monomorphic/polymorphic lesions and matched controls. miR-17, controls vs monomorphic/polymorphic lesions, $p = 0.039$; miR-19, controls vs monomorphic/polymorphic lesions, $p = 0.044$; miR-106a, controls vs monomorphic/polymorphic lesions, $p = 0.009$, by one-way ANOVA.